» Articles » PMID: 2465343

Identification of an Encephalitogenic Determinant of Myelin Proteolipid Protein for SJL Mice

Overview
Journal J Immunol
Date 1989 Mar 1
PMID 2465343
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

PLP is the major protein constituent of central nervous system myelin. We have previously shown that SJL/J (H-2s) mice develop an acute form of EAE after immunization with PLP. The purpose of the present study was to identify an encephalitogenic determinant of PLP for SJL mice. We immunized SJL/J mice with a synthetic peptide identical to residues 130-147 QAHSLERVCHCLGKWLGH of murine PLP, a sequence having an amphipathic alpha-helical conformation. Although it did not induce disease, an overlapping peptide containing residues 139-154 HCLGKWLGHPDKFVGI was encephalitogenic. Immunization with this peptide induced severe clinical and histologic EAE in 3 of 20 mice. T cell enriched ILN cells from these mice responded specifically (3H-thymidine incorporation) to this peptide as well as to shorter analogues of this domain containing serine in place of cysteine at residues 138 and 140. Immunization with the serine-substituted PLP peptides 137-151 VSHSLGKWLGHPDKF and 139-151 HSLGKWLGHPDKF induced severe, acute EAE in 4 of 9 and 15 of 15 SJL mice, respectively, and their T cell enriched ILN cells responded not only to the analogues, but also to the native PLP sequence 139-154. These results indicate that residues 139-151 of murine PLP is an encephalitogenic determinant for SJL mice. Furthermore, like the PLP encephalitogenic domain for SWR (H-2q) mice, this determinant is also a T cell epitope with a coding sequence at the end of an exon.

Citing Articles

Brain organoid methodologies to explore mechanisms of disease in progressive multiple sclerosis.

Simoes-Abade M, Patterer M, Nicaise A, Pluchino S Front Cell Neurosci. 2025; 18:1488691.

PMID: 39744673 PMC: 11688374. DOI: 10.3389/fncel.2024.1488691.


Life history of a brain autoreactive T cell: From thymus through intestine to blood-brain barrier and brain lesion.

Kawakami N, Wekerle H Neurotherapeutics. 2024; 21(6):e00442.

PMID: 39237437 PMC: 11585894. DOI: 10.1016/j.neurot.2024.e00442.


Active Induction of a Multiple Sclerosis-Like Disease in Common Laboratory Mouse Strains.

Orian J, Maxwell D, Lim V Methods Mol Biol. 2023; 2746:179-200.

PMID: 38070090 DOI: 10.1007/978-1-0716-3585-8_15.


Immune Modulation by Antigenic Peptides and Antigenic Peptide Conjugates for Treatment of Multiple Sclerosis.

Mahadik R, Kiptoo P, Tolbert T, Siahaan T Med Res Arch. 2022; 10(5).

PMID: 36381196 PMC: 9648198. DOI: 10.18103/mra.v10i5.2804.


The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A review.

Saez-Calveras N, Brewster A, Stuve O Front Mol Neurosci. 2022; 15:1017484.

PMID: 36311030 PMC: 9606595. DOI: 10.3389/fnmol.2022.1017484.